Commentary Open Access
Volume 2 | Issue 1 | DOI: https://doi.org/10.33696/cardiology.2.009
Commentary on: Structural Basis of the Activation of Heterotrimeric Gs-Protein by Isoproterenol-Bound Beta 1- Adrenergic Receptor
Liang Jing1,2, Lan Zhu1,2, Wei Liu1,2,*
- 1DBiodesign Center for Applied Structural Discovery, Biodesign Institute, Arizona State University, 727 East Tyler Street, Tempe, AZ 85287, United States
- 2School of Molecular Sciences, Arizona State University, 551 East University Drive, Tempe, AZ 85287, United States
Corresponding Author
Lan Zhu, lan.zhu@asu.edu
Wei Liu, w.liu@asu.edu
Received Date: January 28, 2021
Accepted Date: April 14, 2021
Jing L, Zhu L, Liu W. Commentary on “Structural Basis of the Activation of Heterotrimeric Gs-Protein by Isoproterenol- Bound ?1-Adrenergic Receptor”. J Clin Cardiol. 2021; 2(1):15-18.
Copyright: © 2021 Jing L, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Recommended Articles
Commentary on: Structural Basis of the Activation of Heterotrimeric Gs-Protein by Isoproterenol-Bound Beta 1- Adrenergic Receptor
G protein coupled receptors (GPCRs) comprise a large superfamily of transmembrane proteins containing more than 800 unique family members. Critically, GPCRs mediate most of the cell responses to extracellular stimuli including hormones, neurotransmitters, light, taste, etc.
Estimated Plasma Volume Status (ePVS) for Diastolic Heart Failure in the Intensive Care Unit: A Retrospective Cohort Study
Diastolic heart failure (DHF) is also be regarded as heart failure with preserved ejection fraction (HFpEF), is estimated to occur in 40 to 50% of patients with HF. More than 70% of HF patients over the age of 65 had HFpEF, and the incidence and prevalence of HFpEF has been increased by 10% every 10 years in comparison to HF with reduced ejection fraction (HFrEF), and this gap is expected to widen in the coming years.
Metformin in Patients with Chronic Heart Failure
Heart failure affects 1-2% of the adult population in developed countries and the lifetime risk of a heart failure diagnosis is 20%. Patients with heart failure have markedly reduced life expectancy, physical capacity and quality of life. One-year all-cause mortality rates for heart failure patients range between 7 and 17% and the yearly hospitalization rate can be as high as 44%.
The Use of a New Type of Heart Rate-controlled Training System HeartGo® for Patients with Chronic Heart Failure on the Pedelec
Secondary prevention of cardiovascular disease such as heart failure includes regular physical activity with endurance and strength training, which is used for this purpose with high prevalence. Early rehabilitation should begin in hospital (phase I), be continued in a rehabilitation clinic or as an outpatient close to home (phase II), and then (phase III) preferably in outpatient heart groups (AHG).
Beta 3-Adrenergic Receptor (β3-AR) Activation at the End of Sustained Ischemia and/or Early Reperfusion may Prove to be a Valuable Cardioprotective Strategy
The contribution of β3-AR activation towards ischemiareperfusion (IR) damage largely depends on the disease stage, severity, experimental model as well as drug specificities which should be considered when investigating β3-AR pharmacology for potential therapeutic applications. These conceptions largely contribute to the discrepancies of the subsequent role of β3-AR activation in the cardiovascular disease process.